Cargando…

The journey of remdesivir: from Ebola to COVID-19

Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe acute respiratory syndrome (SARS)-CoV and Middle...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardo, Joe, Shukla, Ashutosh M, Chamarthi, Gajapathiraju, Gupte, Asmita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250494/
https://www.ncbi.nlm.nih.gov/pubmed/32547625
http://dx.doi.org/10.7573/dic.2020-4-14
_version_ 1783538773074640896
author Pardo, Joe
Shukla, Ashutosh M
Chamarthi, Gajapathiraju
Gupte, Asmita
author_facet Pardo, Joe
Shukla, Ashutosh M
Chamarthi, Gajapathiraju
Gupte, Asmita
author_sort Pardo, Joe
collection PubMed
description Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV. Currently, there are no proven antiviral therapies for COVID-19. Numerous clinical trials have been initiated to identify an effective treatment. One leading candidate is remdesivir (GS-5734), a broad-spectrum antiviral that was initially developed for the treatment of Ebola virus (EBOV). Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated. In this narrative review, we provide an overview of Ebola and coronavirus outbreaks. We then summarize preclinical and clinical studies of remdesivir for Ebola and COVID-19.
format Online
Article
Text
id pubmed-7250494
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-72504942020-06-15 The journey of remdesivir: from Ebola to COVID-19 Pardo, Joe Shukla, Ashutosh M Chamarthi, Gajapathiraju Gupte, Asmita Drugs Context Review Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV. Currently, there are no proven antiviral therapies for COVID-19. Numerous clinical trials have been initiated to identify an effective treatment. One leading candidate is remdesivir (GS-5734), a broad-spectrum antiviral that was initially developed for the treatment of Ebola virus (EBOV). Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated. In this narrative review, we provide an overview of Ebola and coronavirus outbreaks. We then summarize preclinical and clinical studies of remdesivir for Ebola and COVID-19. BioExcel Publishing Ltd 2020-05-22 /pmc/articles/PMC7250494/ /pubmed/32547625 http://dx.doi.org/10.7573/dic.2020-4-14 Text en Copyright © 2020 Pardo J, Shukla AM, Chamarthi G, Gupte A. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Review
Pardo, Joe
Shukla, Ashutosh M
Chamarthi, Gajapathiraju
Gupte, Asmita
The journey of remdesivir: from Ebola to COVID-19
title The journey of remdesivir: from Ebola to COVID-19
title_full The journey of remdesivir: from Ebola to COVID-19
title_fullStr The journey of remdesivir: from Ebola to COVID-19
title_full_unstemmed The journey of remdesivir: from Ebola to COVID-19
title_short The journey of remdesivir: from Ebola to COVID-19
title_sort journey of remdesivir: from ebola to covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250494/
https://www.ncbi.nlm.nih.gov/pubmed/32547625
http://dx.doi.org/10.7573/dic.2020-4-14
work_keys_str_mv AT pardojoe thejourneyofremdesivirfromebolatocovid19
AT shuklaashutoshm thejourneyofremdesivirfromebolatocovid19
AT chamarthigajapathiraju thejourneyofremdesivirfromebolatocovid19
AT gupteasmita thejourneyofremdesivirfromebolatocovid19
AT pardojoe journeyofremdesivirfromebolatocovid19
AT shuklaashutoshm journeyofremdesivirfromebolatocovid19
AT chamarthigajapathiraju journeyofremdesivirfromebolatocovid19
AT gupteasmita journeyofremdesivirfromebolatocovid19